Patents by Inventor Gary lee Warren

Gary lee Warren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11957731
    Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.
    Type: Grant
    Filed: September 2, 2022
    Date of Patent: April 16, 2024
    Assignee: CSL Limited
    Inventors: Yvonne Vucica, Gary Lee Warren
  • Patent number: 11732028
    Abstract: A method for purifying Apo A-I is provided including the steps of providing a solution comprising Apo A-I and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nm to 35 nm to thereby reduce viral contamination of the Apo A-I. An Apo A-I preparation is provided having at least a 12 log LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-I and methods of treating diseases disorders or conditions.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: August 22, 2023
    Assignee: CSL Limited
    Inventors: Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki
  • Publication number: 20230142696
    Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.
    Type: Application
    Filed: September 2, 2022
    Publication date: May 11, 2023
    Applicant: CSL Limited
    Inventors: Yvonne Vucica, Gary Lee Warren
  • Patent number: 11464828
    Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: October 11, 2022
    Assignee: CSL Limited
    Inventors: Yvonne Vucica, Gary Lee Warren
  • Patent number: 11279750
    Abstract: The present invention relates to processes of obtaining Apo A-1 from an Apo A-1 containing protein fraction (A), comprising suspending—the Apo A-1 containing protein fraction (A) in a buffer solution (B), removing impurities from the suspension while keeping the Apo A-1 proteins solubilized, followed by precipitating Apo A˜I from the suspension and collecting the Apo A-1 precipitate. Apo A-I obtained by such processes, reconstituted HDL obtained from such Apo A-1, and pharmaceutical compositions comprising such Apo A-I and/or reconstituted HDL also are provided.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: March 22, 2022
    Assignee: CSL LIMITED
    Inventors: Yvonne Vucica, Gary Lee Warren
  • Publication number: 20210147509
    Abstract: A method for purifying Apo A-I is provided including the steps of providing a solution comprising Apo A-I and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nm to 35 nm to thereby reduce viral contamination of the Apo A-I. An Apo A-I preparation is provided having at least a 12 log LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-I and methods of treating diseases disorders or conditions.
    Type: Application
    Filed: July 31, 2020
    Publication date: May 20, 2021
    Applicant: CSL Limited
    Inventors: Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki
  • Publication number: 20200397859
    Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.
    Type: Application
    Filed: March 23, 2020
    Publication date: December 24, 2020
    Applicant: CSL Limited
    Inventors: Yvonne Vucica, Gary Lee Warren
  • Patent number: 10730927
    Abstract: A method for purifying Apo A-I is provided including the steps of providing a solution comprising Apo A-I and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nm to 35 nm to thereby reduce viral contamination of the Apo A-I. An Apo A-I preparation is provided having at least a 12 log LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-I and methods of treating diseases disorders or conditions.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: August 4, 2020
    Assignee: CSL LIMITED
    Inventors: Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki
  • Publication number: 20200223902
    Abstract: The present invention relates to processes of obtaining Apo A-1 from an Apo A-1 containing protein fraction (A), comprising suspending—the Apo A-1 containing protein fraction (A) in a buffer solution (B), removing impurities from the suspension while keeping the Apo A-1 proteins solubilized, followed by precipitating Apo A˜I from the suspension and collecting the Apo A-1 precipitate. Apo A-I obtained by such processes, reconstituted HDL obtained from such Apo A-1, and pharmaceutical compositions comprising such Apo A-I and/or reconstituted HDL also are provided.
    Type: Application
    Filed: September 18, 2019
    Publication date: July 16, 2020
    Applicant: CSL LIMITED
    Inventors: Yvonne Vucica, Gary Lee Warren
  • Patent number: 10603355
    Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: March 31, 2020
    Assignee: CSL LIMITED
    Inventors: Yvonne Vucica, Gary Lee Warren
  • Patent number: 10421799
    Abstract: The present invention relates to processes of obtaining Apo A-1 from an Apo A-1 containing protein fraction (A), comprising suspending the Apo A-1 containing protein fraction (A) in a buffer solution (B), removing impurities from the suspension while keeping the Apo A-1 proteins solubilized, followed by precipitating Apo A˜I from the suspension and collecting the Apo A-1 precipitate. Apo A-I obtained by such processes, reconstituted HDL obtained from such Apo A-1, and pharmaceutical compositions comprising such Apo A-I and/or reconstituted HDL also are provided.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: September 24, 2019
    Assignee: CSL LIMITED
    Inventors: Yvonne Vucica, Gary Lee Warren
  • Publication number: 20190119354
    Abstract: A method for purifying Apo A-I is provided including the steps of providing a solution comprising Apo A-I and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nm to 35 nm to thereby reduce viral contamination of the Apo A-I. An Apo A-I preparation is provided having at least a 12 log LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-I and methods of treating diseases disorders or conditions.
    Type: Application
    Filed: July 20, 2018
    Publication date: April 25, 2019
    Applicant: CSL Limited
    Inventors: Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki
  • Publication number: 20190015476
    Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.
    Type: Application
    Filed: February 12, 2018
    Publication date: January 17, 2019
    Applicant: CSL Limited
    Inventors: Yvonne Vucica, Gary Lee Warren
  • Publication number: 20180298080
    Abstract: The present invention relates to processes of obtaining Apo A-I from an Apo A-I containing protein fraction (A), comprising suspending the Apo A-I containing protein fraction (A) in a buffer solution (B), removing impurities from the suspension while keeping the Apo A-I proteins solubilized, followed by precipitating Apo A˜I from the suspension and collecting the Apo A-I precipitate. Apo A-I obtained by such processes, reconstituted HDL obtained from such Apo A-I, and pharmaceutical compositions comprising such Apo A-I and/or reconstituted HDL also are provided.
    Type: Application
    Filed: January 12, 2018
    Publication date: October 18, 2018
    Applicant: CSL LIMITED
    Inventors: Yvonne Vucica, Gary Lee Warren
  • Patent number: 10087235
    Abstract: A method for purifying Apo A-I is provided including the steps of providing a solution comprising Apo A-I and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nrn to 35 nm to thereby reduce viral contamination of the Apo A-I. An Apo A-f preparation is provided having at least a 12 log LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-I and methods of treating diseases disorders or conditions.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: October 2, 2018
    Assignee: CSL LIMITED
    Inventors: Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki
  • Patent number: 9925236
    Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: March 27, 2018
    Assignee: CSL LIMITED
    Inventors: Yvonne Vucica, Gary Lee Warren
  • Patent number: 9890203
    Abstract: The present invention relates to processes of obtaining Apo A-1 from an Apo A-1 containing protein fraction (A), comprising suspending—the Apo A-1 containing protein fraction (A) in a buffer solution (B), removing impurities from the suspension while keeping the Apo A-1 proteins solubilized, followed by precipitating Apo A˜I from the suspension and collecting the Apo A-1 precipitate. Apo A-I obtained by such processes, reconstituted HDL obtained from such Apo A-1, and pharmaceutical compositions comprising such Apo A-I and/or reconstituted HDL also are provided.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: February 13, 2018
    Assignee: CSL LIMITED
    Inventors: Yvonne Vucica, Gary Lee Warren
  • Publication number: 20160176946
    Abstract: The present invention relates to processes of obtaining Apo A-1 from an Apo A-1 containing protein fraction (A), comprising suspending—the Apo A-1 containing protein fraction (A) in a buffer solution (B), removing impurities from the suspension while keeping the Apo A-1 proteins solubilized, followed by precipitating Apo A˜I from the suspension and collecting the Apo A-1 precipitate. Apo A-I obtained by such processes, reconstituted HDL obtained from such Apo A-1, and pharmaceutical compositions comprising such Apo A-I and/or reconstituted HDL also are provided.
    Type: Application
    Filed: June 5, 2014
    Publication date: June 23, 2016
    Applicant: CSL LIMITED
    Inventors: Yvonne Vucica, Gary Lee Warren
  • Publication number: 20160176947
    Abstract: A method for purifying Apo A-l is provided including the steps of providing a solution comprising Apo A-l and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nrn to 35 nm to thereby reduce viral contamination of the Apo A-l. An Apo A-f preparation is provided having at least a 12 LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-l and methods of treating diseases disorders or conditions.
    Type: Application
    Filed: August 8, 2014
    Publication date: June 23, 2016
    Applicant: CSL Limited
    Inventors: Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki
  • Publication number: 20150306176
    Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.
    Type: Application
    Filed: October 31, 2013
    Publication date: October 29, 2015
    Applicant: CSL Limited
    Inventors: Yvonne Vucica, Gary Lee Warren